Partnering & Licensing Services
Licensing-Joint Ventures Negotiations-Investor Introductions and Positioning-Building Awareness in the Medical and Investor Communities
Strong Footprint in Emerging Markets for Two Decades
Investors, medical device, biotechnology and pharmaceutical companies are looking to emerging markets for growth. We think the current capital crunch can provide unique opportunities for innovator technology companies and our ability to match them with the right partner can help maximize technology valuation.
Innovara’s footprint in emerging markets for the past two decades makes us unique in understanding and identifying the right ethical partners who can truly maximize novel technologies. Innovara has consultants that live in Korea, Taiwan, China, Japan, Thailand, Australia, India, Egypt, Turkey, Saudi Arabia, Argentina, France, and the US and also has consultants that are from and/or cover other parts of EU, SE Asia, Russia, Israel and other parts of Asia/Pacific and the Indian subcontinent, Latin America, Africa and Middle East/Gulf Region. By living and working locally and regionally, we know firsthand about various local business practices, medical perspectives, and business relationships which could impact both negotiations as well as product success.
Who We Know and Where We Work is Key to Our Success
Relationships at the highest levels of our client organizations are one of the keys to our success. Our clients are long term clients by the very nature of the strategic advice and partnerships that we form. We have long term personal relationships with CEOs and Presidents and other leaders of specific corporate divisions/countries, governments, and medicine. Additionally we have many contacts within our client companies and the financial industry due to our various businesses, prior business experiences, and our cultivated long term relationships. This translates into a very unique understanding of the culture and the strategies of these specific partners in various geographic regions.
Uniquely Positioned to Represent Breakthrough Technologies
We currently specialize in disease treatment areas where we can leverage our existing depth of contacts from all of our business areas. Innovara maintains strong relationships with major academic institutions globally due to medical thought leadership development initiatives, organization of global and international educational collaborations of the current and future medical leaders, and other educational exchanges as a result of our consulting business. Program expertise includes important disease areas globally and in emerging growth markets, including diabetes, hepatology, oncology, cardiology, CNS, respiratory, infectious disease, women’s healthcare, and also including diagnostics and devices used to advance medical decision-making and ultimately patient outcomes. We keep our involvement within the research and academic community at arms’ length such that we may utilize these thought leaders to assist in a rigorous and objective due diligence process in evaluating product or technology candidates without commercial influence.
Trust is Key to Building Strong Partnerships
Innovation requires partners that have the ability to see the possibilities, to assess and communicate risks honestly, and to integrate and facilitate useful connections which build and add value. Innovara provides a supportive approach which values integrity, confidentiality, trust, and strategic creativity as its cornerstones. We don’t just identify partners, but help build the partnership to ensure success. We also can provide strategic positioning, elevating awareness of the products/technologies.
Business Development Team
Innovara has a team of personnel dedicated to business development services which include licensing, joint venture negotiations, investor introductions-presentations-positioning, building awareness within the medical and investor communities, strategic branding and advisory. . The team is headed by Margot DeFrance, Executive Vice President (former Healthcare Equity Strategist from Citi and former Abbott Diagnostics executive), supported by both HQ and regional VPs from these emerging growth market areas and from EU.
Track Record: We have completed multiple licensing deals in the $2-5M upfront payment range (some included associated capital investment or additional market options beyond royalty agreements). We have been the strategic advisor for IPOs, strategic advisors to major pharma corporations in the assessment of the development product portfolio prior to merger, strategic advisor /deal structure team for acquisitions, and consultants to biotech center development at key centers of academic and research based medicine. Our success stems from leveraging our specific disease treatment knowledge obtained across our various business divisions, our database of contacts, our candidate selection process, and our deal structure and negotiation experience.
To learn more about Innovara’s business development partnering & licensing services please contact Margot DeFrance, Executive Vice President, Business Development.